Venartel

Quick links

Choose a section

Quick links to important sections

Advertisements

Venartel

Advertisements
Advertisements
Advertisements

Overview of Venartel

Property Description
Active ingredient Diosmin and Hesperidin (Micronized Purified Flavonoid Fraction)
Form Coated Tablets, Granules for Oral Suspension
Pharmacological class Phlebotonic, Vasoprotective
General purpose Support for vascular structure and circulation
Origin Derived (purified bioflavonoid from plant sources)

Venartel is a pharmaceutical preparation classified as a phlebotonic and vasoprotective medicine, specifically developed to enhance the tone of veins and protect the integrity of the vascular system. It belongs to the pharmacological group of agents used for vascular support that includes naturally occurring flavonoids and similar synthetic products. This classification confirms the drug is designed to act directly on the blood vessels, supporting the return of blood flow.


Composition: Diosmin, Hesperidin, and the Role of Micronization

The primary active foundation of Venartel is the Micronized Purified Flavonoid Fraction (MPFF), a plant-derived complex featuring the key bioflavonoids Diosmin and Hesperidin. The MPFF composition typically consists of 90% Diosmin and 10% other active flavonoids, expressed as Hesperidin. This standardized ratio is used in vascular health and is established as a clinically recognized formulation for this purpose. The drug is presented as an orally administered solid dosage form, typically as coated tablets or granules for oral suspension. The utilization of a micronized form is a key pharmaceutical feature; this process significantly reduces the particle size of the active substances to enhance their absorption from the gastrointestinal tract, ensuring the body can utilize the compound effectively.


What is the General Purpose of a Phlebotonic Agent?

The general purpose of a phlebotonic agent like Venartel is to alleviate discomfort and symptomatic burdens associated with compromised venous circulation. By enhancing venous tone and strengthening capillary integrity, the medicine helps to counter the tendency of fluid to leak from small vessels into surrounding tissues. This targeted action supports healthier blood return and microcirculation, which often translates to a reduction in feelings of heaviness, fatigue, and swelling in the affected limbs, a typical presentation for individuals seeking chronic vascular support.

Regulatory References

  1. Daflon 500 mg Summary of Product Characteristics (SmPC) (Rwanda FDA)
Advertisements

What side effects are possible with Venartel?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Venartel (Diosmin and Hesperidin) as documented in official government regulatory documents.

Adverse reactions are primarily classified by frequency and grouped into System-Organ Classes.

Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions are associated with the Gastrointestinal system.

Frequency Classification Officially Listed Adverse Reactions
Common (1 to 10 users out of 100) Diarrhea, Dyspepsia, Nausea, Vomiting
Uncommon (1 to 10 users out of 1,000) Colitis
Rare (1 to 10 users out of 10,000) Dizziness, Headaches, Malaise, Rash, Pruritus, Urticaria
Frequency not known Abdominal pain, Isolated oedema (face, eyelids, lips), Quincke's oedema

Serious Adverse Reactions and Safety Constraints

The most clinically significant safety element documented is the potential for Hypersensitivity reactions. This includes signs of allergic response and the specific listing of Quincke's oedema (angioedema), which is documented as an exceptional occurrence with a frequency that is not known. The medicine is contraindicated in individuals with a known hypersensitivity to the active substance or its excipients.

Population-Specific Safety Status

Official regulatory documents state that the safety and efficacy have not been established for the paediatric population (children and adolescents under 18 years of age). Due to limited or non-existent data, use is generally advised to be avoided as a precautionary measure during pregnancy and breast-feeding.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The following information details the documented presentations and required actions for a Venartel overdose, strictly based on official government regulatory documents.


Documented Overdose Presentations

Clinical manifestations reported in association with Venartel overdosage range from less severe to life-threatening. Common reported signs include somnolence, dizziness, nausea, vomiting, and tachycardia (rapid heart rate).

Serious outcomes documented in regulatory warnings include seizures, altered consciousness (including coma), Serotonin Syndrome (a potentially fatal condition), and severe cardiovascular events such as ventricular dysrhythmias and QRS widening (an ECG abnormality). The risk of death is documented as increased compared to some other antidepressant classes.

Immediate Emergency Actions

There is no known specific antidote for Venartel overdose. Treatment is focused on supportive and symptomatic care, as guided by healthcare professionals.

When to Seek Urgent Help:

Condition Required Action (as labeled)
Any suspected overdose (even if asymptomatic) Call the Poison Control Center immediately.
Collapse, seizure, trouble breathing, or inability to awaken Call Emergency Services (e.g., 911) immediately.

Continuous cardiac monitoring is an essential procedural requirement for overdose management, particularly due to the risk of delayed cardiac or neurological events with extended-release formulations.

Advertisements

Therapeutic Uses of Venartel

What Venartel Treats: Main Uses and Benefits

Venartel, classified as a phlebotonic and vasoprotective agent, is used for symptomatic management across relevant vascular domains, supporting patients experiencing conditions associated with issues in venous and microcirculatory integrity. It is commonly used for treating the symptoms and signs of organic and idiopathic chronic venous disease of the lower limbs and the symptoms of acute hemorrhoidal attacks.

The medicine helps address symptom clusters related to physical discomfort, commonly used in conditions characterized by periods of heightened symptoms. It is applied in scenarios where additional management of discomfort is required, relevant in contexts involving heightened systemic burden, such as episodes where symptoms become more disruptive. The preparation supports patients in managing symptoms related to inflammatory or irritative states, including persistent feelings of heaviness, leg pain, and swelling.


Quick Fact: Symptomatic Assistance for Discomfort and Swelling Venartel supports patients managing symptoms of Chronic Venous Insufficiency (CVI) like leg heaviness, nocturnal cramps, and localized edema, and may assist with symptomatic assistance during acute hemorrhoidal attacks involving pain and burning.

Regulatory References

  1. FDA Verification Portal
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Venartel?

This section outlines the official population eligibility and restriction rules for using Venartel (Micronized Purified Flavonoid Fraction), based strictly on government-approved regulatory documents.

Contraindicated and Prohibited Use

Venartel is absolutely contraindicated for patients with a known hypersensitivity or allergy to the active substance (Diosmin or Hesperidin) or to any of the product's excipients. This is the sole formal prohibition in the regulatory labeling.

Restrictions Based on Age and Physiological Status

  • Adult Population: The medicine is intended for use in individuals who are 18 years of age and older.
  • Pediatric Population: Use in children and adolescents under 18 is not recommended. Regulatory documents state that safety and efficacy have not been established in this age group.
  • Pregnancy and Lactation: Use during pregnancy is preferable to avoid as a precautionary measure due to limited human data. Breastfeeding must be avoided during treatment because it is unknown whether the active substance is excreted in human milk.

Conditional Use Limitations

Administration for acute hemorrhoidal attacks is designated as short-term treatment. Use is restricted and requires review if symptoms persist for more than 15 days. No absolute contraindications are formally listed for renal or hepatic impairment.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Venartel (Diosmin and Hesperidin/MPFF) is characterized by the current regulatory status that documents an absence of known or clinically relevant drug interactions. The information provided in official government sources regarding co-administration is based on formal regulatory conclusions.

Drug-Drug and Contraindications

No specific medicinal products or substances are officially listed as contraindicated due to a documented interaction risk with Venartel. Regulatory summaries state that no cases of drug interaction have been reported since the marketing of the product. This regulatory position confirms the absence of formal restrictions for co-administration.

Metabolic and Exposure Profile

Formal interaction studies on the product have not been performed, and therefore, the regulatory labeling does not contain specific statements regarding metabolic interactions (such as involvement with CYP enzymes) or transporter-mediated interactions. No substances are officially documented to alter the exposure (e.g., increase or decrease plasma levels) of Venartel or other co-administered medicines.

Substances and Timing Rules

No formal warnings regarding interactions with alcohol, herbal products, or dietary supplements are documented in the regulatory interaction sections. Furthermore, the official prescribing information does not stipulate mandatory administration-timing separation rules for doses of Venartel and any other medicinal product.

Advertisements

Mechanism of Action

Enhancing Venous Tone and Hemodynamic Flow

This domain covers the drug's effect on the venous smooth muscle cells. The active components prolong the vasoconstrictive signaling of the body's natural neurotransmitter, norepinephrine, by inhibiting its metabolism. This sustained action increases the tension of the vein wall, which decreases the vessel's capacity to hold blood (capacitance) and thereby improves the velocity of blood return, countering the formation of blood pooling (venous stasis).

Protecting Microcirculation and Reducing Fluid Exudation

The second core domain focuses on stabilizing the integrity of small vessels and modulating inflammation. The drug acts by inhibiting the activation and adhesion of inflammatory cells (leukocytes) to the capillary lining, which are key steps in vascular wall damage. This stabilizing mechanism increases capillary resistance and decreases hyperpermeability, which is the direct physiological process that reduces the exudation of plasma fluid and proteins into the surrounding interstitial tissues.

Synergistic Action and Lymphatic Support

The fixed-ratio combination (Diosmin/Hesperidin) is observed to have a synergistic pharmacological interaction that provides a greater anti-exudative and venotonic effect than the individual components alone. Furthermore, the mechanism enhances the contractile activity of the lymphatic system. This complementary support for lymphatic function enhances the clearance of interstitial fluid via modulation of the lymphatic system's contractile activity, regulating tissue fluid balance.

Advertisements

Dosage and Administration Information

Venartel is an orally administered medication that utilizes the Micronized Purified Flavonoid Fraction (MPFF), typically available in 500 mg or 1000 mg tablet strengths. The dosing and duration of use are governed by the condition being addressed.

Administration Scope

Category Instruction
Route of administration Approved exclusively for oral administration.
Dosing schedule Chronic Symptoms: A standard maintenance dose is 1000 mg MPFF daily. Acute Episodes: A fixed, seven-day tiered regimen is followed: 3000 mg daily for the first four days, followed by 2000 mg daily for the subsequent three days.
Timing in relation to meals (if applicable) Administration must occur at mealtimes, with the chronic dose typically taken in two divided portions at midday and in the evening.
Age-group administration rules The safety and efficacy of the product have not been established for use in children and adolescents under 18 years of age.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral solid dosage form (tablet).
Frequency pattern Once-daily for total dose, often administered in divided doses; multi-dose daily for the short-term acute course.
Use-context constraints The use for acute episodes is designated as a short-term, temporary measure only.

Resulting Procedural Structure

Established step sequence:

  • The tablets must be swallowed with water.
  • For maintenance use, the daily dose is typically divided into two portions and taken with the midday and evening meals.
  • If a scheduled dose is missed, it should be taken as soon as remembered, unless it is close to the next dose time, in which case the missed dose should be skipped.

Connection to the overall use protocol (2–4 sentences): The instructions structure the use of Venartel by establishing distinct dosing patterns and durations based on whether the administration is for long-term chronic management or a fixed-duration acute episode. This framework mandates the intake of the oral form in specific divided amounts at mealtimes to define the standardized usage protocol.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Venartel (MPFF)


Evidence for Use in Chronic Venous Disease (CVD) Symptoms

The foundation of the research for Venartel involves multiple well-designed Randomized Controlled Trials (RCTs) and is supported by large Systematic Reviews and Meta-Analyses. These studies explored the compound's application in adult patients across the spectrum of Chronic Venous Disease (CVD) severity. Research was conducted using designs that are relevant in trials assessing short-term or episodic symptom patterns. Studies monitored outcomes related to physical discomfort, including common symptoms such as leg heaviness and pain. Researchers also evaluated objective measurements, such as changes in leg circumference and volume, used to monitor swelling (edema). Findings describe patterns observed in the studies where measurements of these symptoms and edema evolved in the observed populations during the study period.


Evidence for Use During Acute Hemorrhoidal Attacks

Venartel was also studied for its application during conditions involving periods of heightened symptom activity, specifically acute hemorrhoidal attacks. The evidence base here is composed of several Randomized Controlled Trials (RCTs) focusing on very short-term outcomes. Research was conducted during periods of increased symptom activity. Research examined outcomes describing episodic or acute changes, particularly the intensity and duration of local symptoms, including pain and anal bleeding. Studies report that, during these acute episodes, research measured differences in the time course of symptom evolution and the reported need for concomitant pain relief medication.


What Remains Uncertain and Areas for Future Research

Key research limitations include the fact that long-term effects are not fully established; while changes in symptomatic reports were observed, data are still emerging on preventing the long-term functional imbalance associated with CVD progression. Comparative evidence is lacking against certain other therapeutic alternatives. Furthermore, research is limited concerning use in specific subgroups, such as adolescents or pediatric patients. Studies help show what has been observed so far, but research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Venartel (FAQ)


Q: Does Venartel need to be taken indefinitely, or only for a certain period?

A: The use of Venartel for acute (short-term) episodes is associated with a fixed treatment duration, as described in regulatory documents. However, when used for chronic management, official information describes a standard maintenance dose but does not specify a definitive maximum duration for ongoing therapy.


Q: What is the difference between the ingredient in Venartel and the original compound it's based on?

A: Venartel is a pharmaceutical preparation that uses the active substance Micronized Purified Flavonoid Fraction (MPFF), which is derived from plant sources. The term 'micronized' indicates that the particles have been milled to a very small size. This specific manufacturing step, known as micronization, is included in the process with the intention of improving the ingredient’s absorption.


Q: What is the maximum duration of use described in the regulatory documents for Venartel?

A: Regulatory documents define a fixed, short-term treatment regimen when Venartel is administered for acute conditions. Official guidance states that if symptoms related to these acute conditions persist for more than 15 days, a re-evaluation of the condition may be indicated.


Q: Is Venartel considered a natural supplement or a prescription drug?

A: Venartel is classified as a pharmaceutical product, which is a plant-derived bioflavonoid complex, developed to support vascular structure and circulation. The specific regulatory status of the product (such as whether it is prescription-only or available over-the-counter) is determined by the governing health authority in your region.


Q: Can Venartel be used for general wellness or only for specific diagnoses?

A: Official regulatory documents define the specific conditions for which Venartel has been studied and approved. The product is described as an agent used to alleviate discomfort and symptomatic burdens associated with compromised venous circulation. The labeling indicates the product is for specific conditions for which it has regulatory approval.


Q: Is Venartel safe for a person who is over 65 years old?

A: Official documents state that the medicine is intended for use in individuals who are 18 years of age and older. No specific warnings or dosage adjustments are formally listed in the regulatory documents solely for the geriatric population.


Q: What is the list of inactive ingredients found in Venartel tablets?

A: Official product labeling for Venartel lists all components of the tablet. In addition to the active ingredients (Diosmin and Hesperidin), this list details all the inactive ingredients, known as excipients, that are present in the final formulation.


Q: Is Venartel known to affect blood pressure readings?

A: Official documentation describes the drug's effect on blood vessels, specifically targeting venous smooth muscle cells. However, changes to overall blood pressure are not listed among the adverse reactions commonly or uncommonly documented in the official safety information.


Q: Does taking Venartel require any special monitoring by a healthcare provider?

A: Official prescribing information does not stipulate mandatory laboratory tests or specialized monitoring requirements for patients receiving Venartel therapy. As with any medication, any needed monitoring is at the discretion of the prescribing healthcare professional.


Q: How is Venartel different from a standard anti-inflammatory drug?

A: Venartel is primarily classified as a phlebotonic and vasoprotective medicine, meaning it enhances vein tone and protects vessel integrity. While its mechanism involves modulating inflammation and reducing fluid leakage (exudation), its function is described as distinct from that of a standard anti-inflammatory drug.


Q: Is it true that Venartel can cause changes in sleep patterns?

A: Changes in sleep patterns, such as insomnia, are not included among the commonly or uncommonly listed adverse reactions documented in the official safety information for Venartel.


Q: What should be done if a potential drug interaction is suspected while taking Venartel?

A: Since official documents state there are no known drug interactions, the standard safety protocol applies. Regulatory and authoritative medical sources typically state that consulting with a healthcare professional, such as a doctor or pharmacist, is the appropriate step when a potential drug interaction or new symptom is noted.


Q: Does Venartel have any effect on blood sugar levels?

A: Changes to blood sugar levels are not listed among the common or known adverse effects documented in the official prescribing information for Venartel.


Q: Can Venartel be crushed or split if a person has trouble swallowing pills?

A: Official regulatory guidance advises that the tablets must be swallowed whole with water. Modification of the oral dosage form should be discussed with a healthcare professional, as crushing or splitting a tablet may potentially affect how the drug is absorbed by the body.


Q: Does Venartel cause any noticeable changes in mood or anxiety?

A: Mood disturbances or anxiety changes are not listed as adverse reactions of known frequency in the official safety documentation for Venartel.


Q: How does the effectiveness of Venartel compare between men and women?

A: The research evidence used to support the regulatory approval of Venartel is based on studies of adult patients generally. Regulatory documents do not provide specific data or conclusions comparing the effectiveness between men and women.


Q: Does Venartel need to be stored in the refrigerator?

A: Official regulatory documents state that Venartel must be stored at a temperature not exceeding 30 C and must not be frozen. Therefore, it does not require storage in a refrigerator.


Q: Is Venartel a controlled substance?

A: According to regulatory status checks, Venartel is not designated as a controlled substance under federal drug schedules.


Q: Are there specific laboratory tests recommended before starting Venartel?

A: Official prescribing information does not stipulate mandatory laboratory tests recommended before initiating Venartel therapy.


Q: Why do official sources list this specific side effect for Venartel?

A: Adverse reactions, including side effects, are listed in official documents after being observed and documented in rigorous clinical studies or during post-marketing surveillance. This practice is consistent with regulatory reporting standards for pharmaceutical products.


Q: Do lifestyle changes need to be made while taking Venartel?

A: Official usage protocol does not mandate specific lifestyle changes, but it does specify that administration must occur at mealtimes.

Advertisements

How should Venartel be stored and disposed of?

Venartel (Diosmin/Hesperidin) must be stored and disposed of according to strict guidelines defined in official regulatory documents to maintain the stability of the active ingredient and protect the environment.

Storage Category Official Requirement
Temperature Store at a temperature not exceeding 30 C; do not freeze.
Protection Keep the medicine in its original outer packaging to protect it from moisture.
Child Safety Keep out of the sight and reach of children (a mandatory safeguard).
Disposal Do not throw away unused or expired medicine via wastewater or household waste; consult a pharmacist for authorized disposal procedures.

These requirements ensure the product remains stable until its expiration date and that the pharmaceutical waste is handled safely and responsibly.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Venartel found in:

A-Z Index: